Loading
Alimera Sciences Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Morgan Adam, was filed 19 May 2023.
Alimera Sciences Inc: what insiders have been doing
Alimera Sciences Inc, founded in 2003, is a Healthcare & Pharma company based in Alpharetta, United States. Its directors and officers file their transactions with SEC (Form 4). Alimera Sciences Inc has had no insider filing for more than a year; the last one goes back to 18 September 2024.
Since 2016, the database holds 25 purchases and 34 sales by insiders of the company.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
206
Thresholds
n/a
Buy Volume
€3M
25 ops. · all time
Sell Volume
€5M
34 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$69.5M
Gross profitUS$60.2M87% margin
Net income-US$17.3M-24.9% margin
Last declaration on 18 September 2024
Declarations206 total
324,018 sharesCommon StockSEC:0001104659-24-101112:0
500 sharesCommon StockSEC:0001104659-24-101109:0
118,274 sharesCommon StockSEC:0001104659-24-101105:0
10,000 sharesCommon StockSEC:0001104659-24-101114:0
187,756 sharesCommon StockSEC:0001104659-24-101113:0
16,835,154 sharesCommon Stock, par value $0.01 per share ("Common Stock")SEC:0000902664-24-005552:0
225,000 sharesCommon StockSEC:0001104659-24-101107:0
4,178,725 sharesCommon StockSEC:0000921895-24-002133:1
9,429,808 sharesCommon StockSEC:0000921895-24-002133:0
12,103 shares@ US$3.8365.4% of flowCommon StockSEC:0001104659-24-042348:0
2,938 shares@ US$3.86115.9% of flowCommon StockSEC:0001104659-24-003253:0
400,000 shares0Common StockSEC:0000950170-23-051927:0
225,000 shares0Common StockSEC:0000950170-23-051939:0
579,000 shares@ US$3.3924.7% of flowCommon Stock, par value 0.01 per share (Common Stock)SEC:0000902664-23-004790:0
13,431,616 shares@ US$1.7073.7% of flowCommon StockSEC:0000902664-23-004504:1
4,178,725 shares@ US$1.7029.7% of flowCommon StockSEC:0000921895-23-002012:2
2,924,762 shares@ US$2.1025.7% of flowCommon StockSEC:0000921895-23-002012:1
4,845,392 shares@ US$1.7077.5% of flowCommon StockSEC:0000921895-23-002012:0
2,924,761 shares@ US$2.1075.3% of flowCommon Stock, par value $0.01 per share ("Common Stock")SEC:0000902664-23-004504:0
1,401,901 shares@ US$1.7022.5% of flowCommon StockSEC:0000921895-23-001299:0
Canonical exit: 15 Aug 2023 (T+90)
58,000 shares0Common StockSEC:0000899243-23-009832:0
103,000 shares0Common StockSEC:0000899243-23-009830:0
186,000 shares0Common StockSEC:0000899243-23-009828:0
200,919 shares@ US$1.5634100.0% of flowCommon StockSEC:0001140361-23-014284:0
68,000 shares0Common StockSEC:0000899243-23-009831:0
25 of 206 declarations
About Alimera Sciences Inc
Alimera Sciences Inc. is a U.S.-based biopharmaceutical company historically focused on ophthalmology and listed on the NASDAQ market in the United States (United States) under the ticker ALIM until its acquisition by ANI Pharmaceuticals in September 2024. The company was founded in 2003 and built its identity around the development, commercialization, and label expansion of therapies for chronic retinal disease. Its U.S. headquarters had been in Alpharetta, Georgia, which served as its operational and commercial base for many years. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1267602/000126760224000019/0001267602-24-000019-index.htm?utm_source=openai))
Alimera’s core business centered on ILUVIEN, a fluocinolone acetonide intravitreal implant designed to provide long-acting drug delivery inside the eye. The product was developed for diabetic macular edema (DME) and, in certain markets, for chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The company also developed commercial rights around YUTIQ, another ophthalmology asset used in uveitis, reinforcing its expertise in a specialized area with high clinical, regulatory, and commercial barriers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1267602/000126760224000019/alim-20231231x10k.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Alimera was a focused niche player rather than a diversified large-cap pharma company. That specialization helped it cultivate strong relationships with retina specialists and ophthalmologists treating chronic retinal disorders, where differentiation depends on durability, patient convenience, and clinical value rather than scale alone. Historically, the company also built an international footprint, with ILUVIEN commercialized in the United States and in multiple overseas markets, including Europe and parts of the Middle East. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1267602/000126760224000019/alim-20231231x10k.htm?utm_source=openai))
Recent developments have been dominated by ownership change. ANI Pharmaceuticals completed its acquisition of Alimera on September 16, 2024, bringing ILUVIEN and YUTIQ into its broader portfolio. In 2025, ANI disclosed that the FDA approved an expanded U.S. label for ILUVIEN to include NIU-PS, broadening the product’s commercial opportunity. Recent clinical presentations also highlighted comparative data for ILUVIEN in diabetic macular edema, supporting the ongoing evidence package around the asset. For investors, ALIM represents a former niche ophthalmology platform whose standalone equity story has effectively transitioned into a portfolio asset within ANI Pharmaceuticals, with value now driven by execution, label expansion, and commercial monetization rather than independent public-company growth. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1023024/000102302424000088/anipclosing-20240916xexx991.htm?utm_source=openai))
